Gain Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
GANX$1.08-0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Common Stock · · AdditionalPaid-in · · AccumulatedOtherComprehensive · · Accumulated · · · | |||||||||||||||||
| · · Shares · · Amounts · · Capital · · Income (Loss) · · Deficit · · Total | |||||||||||||||||
| Balance as of December 31, 2023 | | 16,206,680 | | $1,621 | | $73,113,079 | | $247,241 | | $(60,783,717) | | $12,578,224 | |||||
| Issuance of shares in at-the-market (ATM) offering (Note 14) | | 1,597,128 | | | 159 | | | 2,950,974 | | | — | | | — | | | 2,951,133 |
| Issuance of shares and warrants in public offering and private placement (Note 14) | | 9,251,003 | | | 926 | | | 10,374,052 | | | — | | | — | | | 10,374,978 |
| Stock-based compensation (Note 15) | | 77,777 | | 7 | | 2,341,213 | | — | | — | | 2,341,220 | |||||
| Changes in defined benefit pension plan obligation (Note 11) | | — | | — | | — | | (132,524) | | — | | (132,524) | |||||
| Foreign currency translation | | — | | — | | — | | (367,240) | | — | | (367,240) | |||||
| Net unrealized gain on available-for-sale securities (Note 5) | | — | | | — | | | — | | | 4,974 | | | — | | | 4,974 |
| Net loss | | — | | | — | | | — | | | — | | | (20,411,191) | | | (20,411,191) |
| Balance as of December 31, 2024 | | 27,132,588 | | $2,713 | | $88,779,318 | | $(247,549) | | $(81,194,908) | | $7,339,574 | |||||
| Issuance of shares in ATM offering (Note 14) | | 6,850,679 | | | 685 | | | 18,058,694 | | | — | | | — | | | 18,059,379 |
| Issuance of shares and warrants in public offering (Note 14) | | 5,176,886 | | | 519 | | | 7,015,558 | | | — | | | — | | | 7,016,077 |
| Stock-based compensation (Note 15) | | — | | | — | | | 1,817,484 | | | — | | | — | | 1,817,484 | |
| Exercise of warrants (Note 14) | | 2,729,069 | | | 274 | | | 3,218,382 | | | — | | | — | | | 3,218,656 |
| Exercise of stock options (Note 15) | | 83,750 | | | 8 | | | 250,251 | | | — | | | — | | | 250,259 |
| RSU vesting (Note 15) | | 100,835 | | | 10 | | | (10) | | | — | | | — | | | — |
| Changes in defined benefit pension plan obligation (Note 11) | | — | | | — | | | — | | | 177,214 | | | — | | 177,214 | |
| Foreign currency translation | | — | | | — | | | — | | | 847,204 | | | — | | 847,204 | |
| Net loss | | — | | | — | | | — | | | — | | | (20,161,099) | | | (20,161,099) |
| Balance as of December 31, 2025 | | 42,073,807 | | $4,209 | | $119,139,677 | | $776,869 | | $(101,356,007) | | $18,564,748 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.